SLC38A3 and hepatocellular carcinoma: Similarly to SLC6A14, loss of intratumoral SLC38A3 mRNA was associated with a 38.3-month median survival outcome of HCC patients, which was significantly less than those highly expressing SLC38A3 at 71.0 months (p < 0.001, HR = 0.56 (0.39–0.79), Figure 5B).